HALO
Halozyme Therapeutics Inc
NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY
$66.41
-0.10% today
Updated 2026-06-05
Market cap
$8.24B
P/E ratio
24.39
P/S ratio
5.46x
EPS (TTM)
$2.85
Dividend yield
—
52W range
$51 – $82
Volume
1.6M
WallStSmart proprietary scores
70
out of 100
Grade: B
Buy
Investment rating
10.0
Growth
A+5.0
Quality
C+9.5
Profitability
A+5.3
Valuation
C+3/9
Piotroski F-Score
Weak
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$80.67
+21.47%
12-Month target
$62.25
-6.26%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy4 Buy3 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 23.10% — above average
+ ROE 158.83% — strong efficiency
+ Free cash flow $176.34M — positive
+ Revenue growth 42.20% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Debt/equity 9.76x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $660.12M | $829.25M | $1.02B | $1.40B | $1.51B | $1.8B |
| Net income | $202.13M | $281.59M | $444.09M | $316.89M | $150.05M | — |
| EPS | — | — | — | — | $2.85 | $8.25 |
| Free cash flow | $235.30M | $373.28M | $468.37M | $644.59M | $176.34M | — |
| Profit margin | 30.62% | 33.96% | 43.74% | 22.69% | 23.10% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-03 | TORLEY, HELEN | Sale | 10,000 | $12.07 |
| 2026-06-03 | TORLEY, HELEN | Buy | 10,000 | $12.07 |
| 2026-06-03 | TORLEY, HELEN | Sale | 6,100 | $69.69 |
Peer comparison
Smart narrative
Halozyme Therapeutics Inc trades at $66.41. representing a P/E of 24.39x trailing earnings. Our Smart Value Score of 70/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.97, it sits in the grey zone. TTM revenue stands at $1.51B. with profit margins at 23.10%.
Frequently asked questions
What is Halozyme Therapeutics Inc's stock price?
Halozyme Therapeutics Inc (HALO) trades at $66.41, on a P/E of 24.4x and a P/S of 5.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Halozyme Therapeutics Inc overvalued?
Halozyme Therapeutics Inc carries a Smart Value Score of 70/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Halozyme Therapeutics Inc (HALO)?
The 12-month analyst consensus target is $80.67, about 21.5% above the current $66.41. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of HALO by 2030?
Our research-backed model puts the 2030 base case at $100.75, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Halozyme Therapeutics Inc's revenue?
Halozyme Therapeutics Inc's trailing twelve-month revenue is $1.51B, and our model projects it reaching about $3.51B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Halozyme Therapeutics Inc's Altman Z-Score is 1.97, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.46x
ROE158.83%
Beta0.87
50D MA$67.43
200D MA$69.24
Shares out0.12B
Float0.12B
Short ratio—
Avg volume1.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—